Hormone blocker added to chemo for bladder cancer: early study halted
Disease control
Terminated
This early study tested adding a testosterone-lowering drug (degarelix) to standard chemotherapy for people with muscle-invasive bladder cancer that has testosterone receptors. Only 2 people enrolled before the study was stopped. The goal was to see if the combination could elimi…
Phase: PHASE1 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC